Ampersand Capital Partners

ProtaGene has named Dr. Matthias Bucerius, as Chief Executive Officer. Matthias joins from Merck KGaA, where he led the CDMO business and brought multiple drug substance sites through FDA and EMA inspections. That combination of commercial leadership and regulatory rigor is a strong fit for ProtaGene, whose advanced analytics sit on the critical path for biologics and cell and gene therapy developers in the US and Europe. Congratulations, Matthias. We look forward to working with you, alongside ProtaGene Presidents Roland Moussa and Mike Stump. https://lnkd.in/g6E755qg

Flagship Biosciences, Inc. has merged with Lanterne Dx, bringing together digital pathology and image analysis expertise with Lanterne Dx's histopathology and biomarker services capabilities. This combination enhances offerings to pharmaceutical, biotech, and academic customers, from tissue-based biomarker development through quantitative image analysis, while increasing overall scale. We're grateful to Tom Turi for his leadership in building Flagship Biosciences and wish him well in retirement, and we're excited for what the combined team will deliver next under Jon Bishop’s leadership. Congratulations to both teams on this milestone. https://lnkd.in/gtkpqsyC

In 2019, Pat Walsh saw an opportunity in a sterile fill/finish facility in Raleigh, NC. He partnered with Ampersand to launch TriPharm, which merged into Alcami less than a year later. What came next: a divestiture, an acquisition, and a successful 2022 sale to GHO Capital and The Vistria Group.

We're proud to celebrate BioPharma BoardRoom’s Women of the Future series, spotlighting five extraordinary women leading innovation at Ampersand Capital Partners and across its portfolio companies. From analytical science to cell and gene therapy manufacturing, these women leaders are shaping the future of biopharma: 🔹 Giovanna Scapin, NanoImaging Services — Seeing Biologics in Action: The Next Frontier in Analytical Science 🔹 Hetal Patel, BIOLOGOS — Scaling Biopharma Without Compromising Quality 🔹 Melanie Fan, Ampersand Capital Partners — The Infrastructure Behind Life Sciences Innovation 🔹 Tathiane Castro, VIVEbiotech — Building Quality Into the Future of Advanced Biopharma 🔹 Susan D'Costa, Genezen — Designing the Next Generation of Cell and Gene Therapies for Scale Giovanna: https://lnkd.in/eYYT5t5R Hetal: https://lnkd.in/eXqgu3CV Melanie: https://lnkd.in/enKUjTMX Tathiane: https://lnkd.in/eZAJRCi9 Susan: https://lnkd.in/egtVBHaN

Purna Pharmaceuticals has strengthened its leadership team with the appointments of Wim Vanderaerden as Operations Director and Bert Van Peteghem as Quality Director and Qualified Person. With decades of pharmaceutical operations and quality experience, Wim and Bert bring valuable expertise as Purna enters its next phase of growth and continues to expand its capabilities for customers. https://lnkd.in/ga7tnnB2

Ampersand Capital Partners has been named to GrowthCap's Top Private Equity Firms of 2026 - our third consecutive year on the list! Herb Hooper, our Managing Partner, shared, "Over the last several years, sector expertise and operational discipline have mattered more than ever. Our team works alongside management to build stronger, more resilient healthcare and life sciences businesses. Being named to this list for a third consecutive year is a meaningful reflection on our consistency, and we're grateful to GrowthCap for recognizing the work we do every day alongside our portfolio companies." For more information on the award selection criteria and methodology, as well as the complete award disclaimer, please visit: https://lnkd.in/gaYQNsdh